Journal article
Imaging markers for Alzheimer disease
Giovanni B Frisoni, Martina Bocchetta, Gael Chételat, Gil D Rabinovici, Mony J de Leon, Jeffrey Kaye, Eric M Reiman, Philip Scheltens, Frederik Barkhof, Sandra E Black, David J Brooks, Maria C Carrillo, Nick C Fox, Karl Herholz, Agneta Nordberg, Clifford R Jack, William J Jagust, Keith A Johnson, Christopher C Rowe, Reisa A Sperling Show all
Neurology | Wolters Kluwer | Published : 2013
Abstract
Revised diagnostic criteria for Alzheimer disease (AD) acknowledge a key role of imaging biomarkers for early diagnosis. Diagnostic accuracy depends on which marker (i.e., amyloid imaging, ¹⁸F-fluorodeoxyglucose [FDG]-PET, SPECT, MRI) as well as how it is measured ("metric": visual, manual, semiautomated, or automated segmentation/computation). We evaluated diagnostic accuracy of marker vs metric in separating AD from healthy and prognostic accuracy to predict progression in mild cognitive impairment. The outcome measure was positive (negative) likelihood ratio, LR+ (LR-), defined as the ratio between the probability of positive (negative) test outcome in patients and the probability of posi..
View full abstract